甲基泼尼松龙琥珀酸钠结构式
|
常用名 | 甲基泼尼松龙琥珀酸钠 | 英文名 | 6alpha-Methylprednisolone sodium succinate |
|---|---|---|---|---|
| CAS号 | 2375-03-3 | 分子量 | 496.525 | |
| 密度 | N/A | 沸点 | 689.6ºC at 760mmHg | |
| 分子式 | C26H33NaO8 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 230.7ºC | |
| 符号 |
GHS08 |
信号词 | Danger |
甲基泼尼松龙琥珀酸钠用途6α-Methylprednisolone 21-hemisuccinate钠盐是一种糖皮质激素, 半衰期较Prednisolone长,是一种有效的抗炎剂。 |
| 中文名 | 甲基泼尼松龙琥珀酸钠 |
|---|---|
| 英文名 | 6α-Methylprednisolone 21-hemisuccinate sodium salt |
| 中文别名 | 甲强龙琥珀酸钠 | 6α-甲基泼尼松龙半瑚珀酸酯 |
| 英文别名 | 更多 |
| 沸点 | 689.6ºC at 760mmHg |
|---|---|
| 分子式 | C26H33NaO8 |
| 分子量 | 496.525 |
| 闪点 | 230.7ºC |
| 精确质量 | 496.207306 |
| PSA | 141.03000 |
| LogP | 0.88460 |
| 外观性状 | 冻干的粉末 |
| 储存条件 | -20°C，密闭，干燥 |
| 符号 |
GHS08 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H351-H360 |
| 警示性声明 | P201-P281-P308 + P313 |
| 个人防护装备 | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| 危害码 (欧洲) | T: Toxic; |
| 风险声明 (欧洲) | R61;R40 |
| 安全声明 (欧洲) | 53-22-36/37/39-45 |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 3 |
| RTECS号 | TU4154060 |
|
Shoe contact dermatitis: a case report of an acute severe reaction to potassium dichromate.
Foot (Edinb.) 22(3) , 141-5, (2012) Shoe contact dermatitis is common in both the pediatric and the adult populations. Severity of the reaction can vary greatly by patient.Health Care Professionals of all types should be familiar with s... |
|
|
Ex vivomodels to evaluate the role of ocular melanin in trans-scleral drug delivery
Eur. J. Pharm. Sci. 46(5) , 475-83, (2012) Trans-scleral delivery is nowadays considered as a possible way to deliver drugs to the posterior segment of the eye. Despite the potentiality of this administration route, there is a lack of fundamen... |
|
|
Efficacy of intraoperative, single-bolus corticosteroid administration to prevent postoperative acute respiratory failure after oesophageal cancer surgery.
Interact. Cardiovasc. Thorac. Surg. 15(4) , 639-43, (2012) Respiratory failure from acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and pneumonia are the major cause of morbidity and mortality following an oesophagectomy for oesophageal ca... |
| MFCD00152612 |
| 11b,17,21-Trihydroxy-6a-methylpregna-1,4-diene-3,20-dione 21-(Sodium Succinate) |
| butanedioic acid, mono[(6α,11β)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl] ester, monosodium salt |
| 4-{2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-triméthyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodécahydro-3H-cyclopenta[a]phénanthrén-17-yl]-2-oxoéthoxy}-4-oxobutanoate de sodium |
| 6alpha-Methylprednisolone sodium succinate |
| Sodium 4-{[(6α,11β)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl]oxy}-4-oxobutanoate |
| 6a-Methylprednisolone 21-succinate sodium |
| EINECS 219-156-8 |
| Methylprednisolone sodium succinate |
| Natrium-4-{2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy}-4-oxobutanoat |
| Butanedioic acid, mono[(6α,11β)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl] ester, sodium salt (1:1) |
| sodium 4-{2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy}-4-oxobutanoate |
| 6α-Methylprednisolone 21-hemisuccinate (sodium salt) |
查看所有供应商和价格请点击：